Should All Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease Receive an SGLT2 Inhibitor?

Authors

  • Arden R Barry (Pro) Rideau Community Health Services
  • Bradley R Mitchelmore (Con) Chilliwack General Hospital, University of British Columbia

DOI:

https://doi.org/10.4212/cjhp.v71i4.2831

Abstract

-

Downloads

Download data is not yet available.

Downloads

Published

2018-09-05

Issue

Vol. 71 No. 4 (2018)

Section

Point Counterpoint / Le pour et le contre

License

Copyright © Canadian Society of Healthcare-Systems Pharmacy.

After publication of a manuscript in the CJHP, the authors of the manuscript must obtain written permission from the CSHP (publications@cshp.ca) before reproducing any text, figures, tables, or illustrations from the work in future works of their own. If a submitted manuscript is declined for publication in the CJHP, all said rights shall revert to the authors. Please note that any forms (e.g., preprinted orders and patient intake forms) used by a specific hospital or other health care facility and included as illustrative material with a manuscript are exempt from this copyright transfer. The CJHP will require a letter from the hospital or health care facility granting permission to publish the document(s).